Historically, clinical guidelines in nephrology have employed race-based creatinine equations to estimate glomerular filtration rate (GFR), a critical metric of kidney function. These equations incorporated race as a factor, often assigning higher estimated kidney function to Black patients under the assumption of greater muscle mass. While intended to fine-tune assessment, these race adjustments inadvertently introduced biases that delayed critical referrals to nephrologists and postponed eligibility for placement on kidney transplant waitlists for Black individuals.

In 2021, a paradigm shift occurred when national guidelines formally prohibited the utilization of race-inclusive GFR estimating equations for transplant listing determinations. Subsequently, in December 2023, the Organ Procurement and Transplantation Network (OPTN) enacted a policy mandating that all U.S. kidney transplant programs adjust wait time calculations for Black candidates disadvantaged by prior race-based estimations. This policy aimed to rectify accumulated disparities by awarding time credits to affected individuals, thus elevating their priority status on transplant waitlists.

This multi-institutional collaborative effort, spearheaded by researchers at Beth Israel Deaconess Medical Center, Brigham and Women’s Hospital, and Boston Medical Center, methodically examined the national kidney transplant database encompassing all procedures performed between January 2022 and June 2025. By meticulously analyzing transplant rates across racial groups and dialysis statuses before and after the OPTN policy implementation, the team sought to quantify the direct consequences of these interventions on transplant access equity.

The study’s findings are compelling: over 21,000 transplant candidates benefited from wait time modifications, gaining an average of 1.7 years of wait time credit. Among Black candidates specifically, the policy corresponded to an increase of 5.3 additional transplants per 1,000 waitlisted individuals. Importantly, enhanced transplant rates were observed not only among candidates listed prior to dialysis initiation but also among those listed afterward, suggesting the policy’s broad efficacy across clinical contexts.

Dr. Rohan Khazanchi, MD, MPH, a resident physician intimately involved in the research, emphasized the societal and clinical import of these findings. He noted that such reparative measures—focused on dismantling harmful race-based clinical algorithms—can truly “move the needle toward health equity.” However, he cautioned that despite these improvements, disparities in transplantation for Black patients endure, underscoring the imperative for ongoing accountability, targeted interventions, and system-wide reforms.

Despite the encouraging results, the authors acknowledge certain limitations and the necessity for further research. Long-term outcomes pertaining to graft survival, patient morbidity, and mortality following these policy adjustments remain to be evaluated thoroughly. Additionally, disparities in the implementation of wait time modifications across transplant centers reveal inconsistent adoption, indicating room for policy enforcement and standardized best practices.

It is essential to recognize that the OPTN policy targets only one aspect of systemic inequity—the legacy effects of race-based kidney function equations. Other barriers to early nephrology care and timely transplant evaluation, including socioeconomic factors, healthcare access disparities, and implicit bias, persist unchecked. Thus, a multifaceted approach combining clinical, policy, and community-level interventions is critical to achieving truly equitable kidney transplantation outcomes.

Dr. Martha Pavlakis, MD, program director of Solid Organ Transplantation at Beth Israel Deaconess Medical Center and senior author of the paper, affirmed the translational value of the research, stating that aligning clinical practice and health policies with principles of fairness and evidence-based medicine has tangible clinical impact. By rectifying wait time inequities, the study reinforces the ethical responsibility of the medical community to foster equitable organ allocation frameworks.

The implications of this research extend beyond kidney transplantation. It provides a compelling case study illustrating how uncritical use of biological race in clinical algorithms can perpetuate health disparities. Revisiting and revising such algorithms must be a priority to ensure that advancements in medicine benefit all populations equitably. This study sets a precedent for re-examining other diagnostic and treatment guidelines where racial adjustments might introduce bias.

Ultimately, this landmark study exemplifies how collaborative efforts spanning clinical institutions, governing bodies, and researchers can drive systemic change. By confronting and correcting embedded biases within clinical decision-making tools, the medical community takes a vital step toward dismantling structural racism and fostering a more just healthcare system. The positive shifts in kidney transplant rates among historically marginalized populations underscore the potential of evidence-based policy reforms to save lives and enhance equity.

As the healthcare landscape continues to evolve, further monitoring and refinement of such policies will be essential. Continuous data collection, patient follow-up, and qualitative assessments concerning patient experiences will enrich understanding and guide future improvements. These endeavors not only benefit Black patients but serve as a model for addressing health inequities across diverse medical specialties and populations.

This study stands as a beacon of hope and a call to action, challenging healthcare professionals, policymakers, and researchers to critically evaluate the embedded assumptions within medical guidelines. By embracing science-driven, equity-oriented policies, the promise of fair and effective transplantation access for all patients, irrespective of race, moves closer to reality.

Subject of Research: Impact of policy changes addressing race-based kidney function equations on kidney transplantation rates among Black patients

Article Title: Wait Time Modifications for Transplant Candidates Affected by Race-Based Kidney Function Estimation

News Publication Date: 9-Mar-2026

Keywords: Renal failure, Kidney, Racial inequality, Transplantation, Nephritis

The study, encompassing an extensive cohort of over 860,000 subjects from diverse nationalities, represents the most comprehensive analysis to date investigating the discordance between creatinine- and cystatin C-based eGFR estimates. This large-scale meta-analysis, part of the Chronic Kidney Disease Prognosis Consortium’s global initiative, meticulously accounted for variables known to distort biomarker readings beyond kidney function itself, such as obesity, smoking habits, and cancer history. Participants underwent simultaneous measurement of both creatinine and cystatin C levels, with subsequent longitudinal follow-ups averaging 11 years, allowing researchers to delineate the long-term clinical implications of biomarker discordance.

What the researchers found was striking—more than a third of hospitalized patients displayed a cystatin C-based eGFR that was at least 30% lower than their creatinine-based eGFR. This sizeable discrepancy signals that creatinine alone may significantly overestimate kidney filtering capacity in a notable proportion of the population, particularly among the elderly and patients burdened with chronic illness. Dr. Morgan Grams, a leading nephrologist and co-corresponding author, emphasizes that accounting for both biomarkers reveals “blind spots” inherent in relying solely on one test, enabling earlier and more accurate detection of kidney impairment that might otherwise go unnoticed.

From a clinical standpoint, this dual assessment strategy holds transformative potential. Kidney function evaluation is pivotal for safe pharmacotherapy, including dosing of nephrotoxic cancer drugs, antibiotics, and a myriad of other medications cleared through renal pathways. The misclassification of kidney health risks could lead to suboptimal treatment regimens, jeopardizing patient safety. Furthermore, the study’s findings demonstrated a clear association between significant cystatin C-based eGFR reductions relative to creatinine levels and elevated risks of heart disease, heart failure, and all-cause mortality. This suggests that cystatin C may capture pathological processes extending beyond renal filtration, potentially reflecting systemic inflammation, vascular injury, or other aging-related mechanisms.

Despite cystatin C’s recognized clinical value and recommendations from Kidney Disease—Improving Global Outcomes (KDIGO) since 2012 endorsing its use, adoption in routine clinical laboratories has lagged dramatically in the United States. The study reveals that less than one percent of hospitalized Americans undergo cystatin C testing, underscoring a critical gap between evidence-based medicine and actual practice. This underutilization persists despite recent availability of in-house cystatin C assays at major laboratory service providers such as Quest Diagnostics and Labcorp, signaling a pressing need for heightened clinician awareness and infrastructural incorporation.

The Chronic Kidney Disease Prognosis Consortium’s collaborative network spans several continents and academic institutions — including NYU Langone Health, University of California San Francisco, Charite-Universitatsmedizin Berlin, and others — enabling a comprehensive global perspective on kidney disease trends and prognostic markers. Their findings echo growing international concerns over the rising prevalence of chronic kidney disease (CKD), now ranked as the ninth leading cause of death globally. Early and accurate detection through improved biomarker use may allow timely therapeutic interventions that avert progression to dialysis-dependent renal failure or transplantation.

Importantly, the research highlights that the subgroup exhibiting pronounced cystatin C-creatinine discordance faced disproportionately severe kidney disease outcomes. This group’s propensity for advanced CKD requiring renal replacement therapy and higher mortality rates solidifies the clinical relevance of monitoring both biomarkers. Additionally, individuals presenting seemingly normal creatinine-based eGFR but substantially lowered cystatin C readings may constitute a hidden population at insidious risk—patients who could benefit from preemptive management strategies.

Technically, the superiority of cystatin C lies in its independence from confounding factors commonly impacting creatinine, such as muscle mass variability, diet, and physical activity levels. These influences frequently compromise the accuracy of creatinine measurements in elderly or chronically ill patients with altered muscle composition. Contrastingly, cystatin C production is stable and less susceptible to such biological interferences, granting it enhanced specificity to genuine kidney filtration rates. The discordance observed consequently may reflect both renal and extrarenal pathological states, offering a more holistic risk assessment tool.

The implications for policymaking and clinical guidelines are substantial. Integrating cystatin C measurements into routine kidney function evaluation could revolutionize diagnostic algorithms, risk stratification, and treatment paradigms for millions worldwide. Healthcare systems and providers should prioritize the expansion of cystatin C testing accessibility and clinician education to harness its full prognostic utility. Dr. Josef Coresh, co-corresponding author and director of NYU Langone’s Optimal Aging Institute, stresses the urgent imperative to bridge the gap between current underuse and the clear benefits conferred by incorporating cystatin C into standard renal function panels.

Summary findings presented at the American Society of Nephrology’s annual Kidney Week and published simultaneously in JAMA further reinforce the call for a paradigm shift in renal diagnostics. This landmark work not only uncovers critical limitations of longstanding clinical practices but also charts an innovative course for more precise, personalized kidney care. In an era of precision medicine, leveraging complementary biomarkers like creatinine and cystatin C emerges as a vital strategy to uncover early disease trajectories, tailor therapies effectively, and ultimately improve patient survival and quality of life.

As CKD prevalence escalates and cardiovascular complications remain the leading cause of morbidity in kidney patients, these insights promise to reshape nephrology practice globally. With cystatin C testing now more broadly available, clinicians have at their disposal a powerful tool to identify vulnerable patients earlier, guide medication dosing with enhanced safety, and intervene before irreversible organ damage occurs.

In conclusion, this study, backed by the National Institutes of Health and the National Kidney Foundation, catalyzes a critical reevaluation of kidney function assessment standards. It exemplifies the value of international scientific collaboration and integrative biomarker research in tackling one of the most pressing public health challenges of our time. Moving forward, the integration of cystatin C and creatinine testing could serve as a new gold standard for nephrological evaluation and cardiovascular risk mitigation, unlocking new frontiers in patient care and disease prevention worldwide.

Subject of Research: People
Article Title: Discordance In Creatinine-and Cystatin-C-Based eGRF and Clinical Outcomes
News Publication Date: 7-Nov-2025
Web References: 10.1001/jama.2025.17578
Keywords: Nephropathies, Renal failure, Heart disease, Heart failure, Biomarkers